Loading patent…
OwnerJean-Francois Tanguayinventor
Estimating the term…
A method of using an estrogen receptor agonist and antagonist to reduce a toxic effect of a cytostatic drug on bone marrow derived cells in a biological system. The methods comprise contacting the cells with a therapeutically effective amount of an estrogen receptor agonist or antagonist, and contacting the cells with a cytostatic agent, whereby the toxic effect of the cytostatic drug on bone marrow derived cells is reduced. Agonists disclosed include 17-beta-estradiol. Antagonists disclosed include antisense nucleic acids and selective estrogen receptor modulators (SERMs). Furthermore, uses and medicaments comprising estrogen receptor agonists and antagonists are provided, as are screening methods for identifying therapeutic candidates for reducing the effect of cytostatic agents, and methods of using estrogen receptor agonists for increasing the proliferation of CD117+ cells in a biological system.
A method of using an estrogen receptor agonist to reduce a toxic effect of a cytostatic drug on bone marrow derived cells in a biological system, comprising contacting the cells with a therapeutically effective amount of the estrogen receptor agonist, and contacting the cells with the cytostatic drug, whereby the toxic effect of the cytostatic drug on bone marrow derived cells is reduced.
11-12. (canceled)
(canceled)
24-25. (canceled)
(canceled)
(canceled)
A method of screening for therapeutic agents for reducing a toxic effect of a cytostatic drug, comprising contacting cells expressing an estrogen receptor with a candidate therapeutic agent, and determining whether said candidate therapeutic agent increases an activity of said estrogen receptor, whereby a higher activity in the presence of the candidate therapeutic agent relative to the absence thereof is an indication that the agent is able to reduce the toxic effect of the cytostatic drug.
32-37. (canceled)
A method of increasing the percentage of CD117+ cells in a biological system, comprising contacting the biological system with a therapeutically effective amount of an estrogen receptor agonist.
40-43. (canceled)
45-50. (canceled)
(canceled)
A method of using an estrogen receptor beta antagonist to reduce a toxic effect of a cytostatic drug on bone marrow derived cells in a biological system, comprising contacting the cells with a therapeutically effective amount of an estrogen receptor beta antagonist, and contacting the cells with a cytostatic drug, whereby the toxic effect of the cytostatic drug on bone marrow derived cells is reduced.
55-56. (canceled)
A method of using a low concentration of paclitaxel or rapamycin in combination with an estrogen receptor agonist to reduce the mortality or growth inhibition of bone marrow-derived cells (BMDCs) comprising contacting a BMDCs population with an estrogen receptor agonist and paclitaxel or rapamycin, whereby the mortality or growth inhibition of BMDCs is reduced as compared to in the absence thereof and wherein the BMDCs population comprises hematopoietic stem cells, mesenchymal stem cells and stromal cells.
Dependencies are inferred from the claim text.